Who is sponsoring NCT04939467?

NCT04939467 is sponsored by Blade Therapeutics.

What drugs are being tested in NCT04939467?

Interventions in NCT04939467: Pirfenidone 267 mg Oral Tablet, Nintedanib 150 mg Oral Capsule, BLD-0409 750 mg Oral Tablet.

What condition does NCT04939467 study?

NCT04939467 studies Drug Drug Interaction.

Is NCT04939467 still recruiting?

NCT04939467 is currently completed. Last updated 15 April 2022.

Last reviewed 2022-04-15 · How we verify

NCT04939467

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

Completed Phase 1 Last updated 15 April 2022

What this trial tests

Phase 1 trial testing Pirfenidone 267 mg Oral Tablet in Drug Drug Interaction in 86 participants. Completed in 1 April 2022.

Timeline

15 October 2021

Primary endpoint
16 December 2021

1 April 2022

Quick facts

Lead sponsor	Blade Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	other
Enrollment	86
Start date	15 October 2021
Primary completion	16 December 2021
Estimated completion	1 April 2022
Sites	1 location across United States

Drugs / interventions tested

Pirfenidone 267 mg Oral Tablet — full drug profile →
Nintedanib 150 mg Oral Capsule
BLD-0409 750 mg Oral Tablet — full drug profile →

Conditions studied

Drug Drug Interaction — all drugs for Drug Drug Interaction →

Sponsor

Blade Therapeutics — full company profile →

Who can join

Adults 18 to 55, any sex, with Drug Drug Interaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 1, Open-Label, Non-Randomized, Fixed Sequence Study to Evaluate the Steady-state Pharmacokinetics of BLD-0409, Nintedanib and Pirfenidone when Administered Concurrently in Healthy Volunteers

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target.
Ntatsoulis K, Karampitsakos T, Tsitoura E, Stylianaki EA, et al · · 2021 · cited 36× · PMID 34671341 · DOI 10.3389/fimmu.2021.687397

Verify or expand the search:

Other Blade Therapeutics trials

Trials by the same sponsor.

NCT05373914 — RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · unknown
NCT04814472 — Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations · Phase 1 · completed
NCT04814498 — Drug-Drug Interaction (DDI) Study in Healthy Volunteers · Phase 1 · completed
NCT04334460 — Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects · Phase 2 · completed
NCT04146805 — Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04939467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Blade Therapeutics
Last refreshed: 15 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04939467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing